Veracyte Inc (VCYT) concluded trading on Thursday at a closing price of $27.51, with 0.45 million shares of worth about $12.25 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -31.23% during that period and on July 03, 2025 the price saw a loss of about -0.25%. Currently the company’s common shares owned by public are about 78.31M shares, out of which, 77.13M shares are available for trading.
Stock saw a price change of 2.61% in past 5 days and over the past one month there was a price change of 3.81%. Year-to-date (YTD), VCYT shares are showing a performance of 28.97% which decreased to -30.53% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $19.73 but also hit the highest price of $47.32 during that period. The average intraday trading volume for Veracyte Inc shares is 1.06 million. The stock is currently trading 1.60% above its 20-day simple moving average (SMA20), while that difference is down -3.11% for SMA50 and it goes to -20.98% lower than SMA200.
Veracyte Inc (NASDAQ: VCYT) currently have 78.31M outstanding shares and institutions hold larger chunk of about 108.17% of that.
The stock has a current market capitalization of $2.15B and its 3Y-monthly beta is at 1.98. PE ratio of stock for trailing 12 months is 65.58, while it has posted earnings per share of $0.42 in the same period. Its PEG reads 1.44 and has Quick Ratio of 4.78 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VCYT, volatility over the week remained 3.37% while standing at 3.48% over the month.
Stock’s fiscal year EPS is expected to rise by 64.52% while it is estimated to increase by 44.54% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on March 20, 2025 offering a Buy rating for the stock and assigned a target price of $45 to it. Coverage by Goldman stated Veracyte Inc (VCYT) stock as a Neutral in their note to investors on December 05, 2024, suggesting a price target of $37 for the stock. On November 15, 2024, Wolfe Research Initiated their recommendations, while on October 16, 2024, UBS Initiated their ratings for the stock with a price target of $43. Stock get a Buy rating from Guggenheim on October 10, 2024.
